Mesa Laboratories Says Believes It Has Liquidity Required To Continue Operations Through Period But Expects Biopharmaceutical Development Division Revenues To Be Lower Than Expected; Says As Of Dec. 31 Has Cash Balance Of $75M
Benzinga Newsdesk